Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
AssigneeMerck Sharp & Dohme Corp.
InventorsEmma Joanne Carlson, Nadia Melanie Rupniak
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment or prevention of depression and/or anxiety by the administration of a combination of CNS-penetrant NK-1 receptor antagonists and an antidepressant or anti-anxiety agent.
Claims14
A method for the treatment or prevention of depression or anxiety, which method comprises oral administration to a patient in need of such treatment or prevention of an amount of a NK-1 receptor antagonist and an amount of an antidepressant or anti-anxiety agent, such that together they give effective relief, wherein said NK-1 receptor antagonist is CNS-penetrant as determined by its ability to inhibit NK-1 receptor agonist-induced foot-tapping in the gerbil, and is effective in the attenuation of separation-induced vocalisations by guinea-pig pups.
An oral pharmaceutical composition comprising a NK-1 receptor antagonist and an antidepressant or anti-anxiety agent, together with at least one pharmaceutically acceptable carrier or excipient, characterised in that said NK-1 receptor antagonist is CNS-penetrant as determined by its ability to inhibit NK-1 receptor agonist-induced foot-tapping in the gerbil, and is effective in the attenuation of separation-induced vocalisations by guinea-pig pups.
A product comprising a NK-1 receptor antagonist and an antidepressant or anti-anxiety agent as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of depression or anxiety, characterised in that said NK-1 receptor antagonist is CNS-penetrant as determined by its ability to inhibit NK-1 receptor agonist-induced foot-tapping in the gerbil, and is effective in the attenuation of separation-induced vocalisations by guinea-pig pups.
Dependencies are inferred from the claim text.